Log in or Sign up for Free to view tailored content for your specialty!
Neurology News
Collaboration to advance small activating RNA therapeutics for central nervous system
A London-based biotech firm has announced a collaboration and licensing agreement with a Japanese pharmaceutical firm for discovery, development and commercialization of small activating RNA therapeutics for rare neurodegenerative diseases.
Amylyx pulls ALS drug Relyvrio from market in US, Canada
Amylyx Pharmaceuticals Inc. announced Relyvrio, its amyotrophic lateral sclerosis therapeutic, will be removed from the market in the United States and Canada, effective immediately.
Log in or Sign up for Free to view tailored content for your specialty!
Neurosurgical ablation system receives limited commercial launch
A Minnesota-based medical technology company announced a limited commercial launch of its OneRF Ablation System, which creates radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
Seizure frequency reduced as much as 85% in phase 1/2a studies of Dravet syndrome drug
Seizure frequency was reduced as much as 85% at 3 months in young patients with Dravet syndrome treated with a proprietary antisense oligonucleotide, according to results of phase 1/2a studies released by the manufacturer.
Education level correlated with functional decline in Black adults with high tau levels
Higher education levels may protect against cognitive and functional difficulties for Black individuals with high levels of tau, indicating Alzheimer’s pathology, according to research from the Journal of Alzheimer’s Disease.
Prolonged use of some hormone therapies may increase risk for brain tumors
The prolonged use of certain progestogen hormone drugs — such as medrogestone, medroxyprogesterone acetate and promegestone — increased the risk for developing intracranial meningioma, according to data published in The BMJ.
Intra-molecular compound advanced as potential disease-modifying therapy for ALS
A Cincinnati-based life sciences company announced that one of its development candidates, ASHA-624, will be advanced as a potential disease modifying therapy for amyotrophic lateral sclerosis.
Eisai submits supplemental biologics license application to FDA for monthly IV Leqembi
Eisai and Biogen have submitted a supplemental biologics license application to the FDA for monthly IV maintenance dosing of Leqembi to treat Alzheimer’s disease in patients with mild cognitive impairment or mild dementia.
Point-of-care brain wave monitoring can help improve concussion care
Despite the brain being one of the most important organs of the body, breakthroughs in brain health, specifically the way we measure cognition, have been largely unchanged in decades.
Regular exercise associated with recommended duration of sleep, reduced insomnia symptoms
Exercise just two to three times a week reduced the risk for multiple insomnia symptoms and extreme sleep durations both short and long, a study published in BMJ Open showed.
-
Headline News
We must make our voices heard and vote in the 2024 election
September 18, 20247 min read -
Headline News
Semaglutide improves glucose control in automated insulin delivery for type 1 diabetes
September 20, 20243 min read -
Headline News
Oncologists, primary care clinicians should be aware of BRCA testing indications in men
September 19, 20244 min read
-
Headline News
We must make our voices heard and vote in the 2024 election
September 18, 20247 min read -
Headline News
Semaglutide improves glucose control in automated insulin delivery for type 1 diabetes
September 20, 20243 min read -
Headline News
Oncologists, primary care clinicians should be aware of BRCA testing indications in men
September 19, 20244 min read